Preclinical Observations on Eribulin for Breast Cancer
Joyce O’Shaughnessy, MD, and Mark Pegram, MD, explain preclinical observations surrounding eribulin and highlight the importance of responses to therapy and tolerability.
Joyce O’Shaughnessy, MD, and Mark Pegram, MD, explain preclinical observations surrounding eribulin and highlight the importance of responses to therapy and tolerability.
